Rentschler: 4th Laupheim Biotech Days to take place 13–14 June 2016
Exciting lectures and discussions on therapeutic fusion proteins.
The Laupheim Biotech Days — formerly known as Laupheimer Zelltage — provide a unique platform for the international exchange of knowledge, ideas and expertise. A comprehensive overview is given and experts discuss cutting-edge technologies and techniques. The 4th Laupheim Biotech Days will take place June 13 to 14, 2016. The event is organized by Rentschler, a leading contract development and manufacturing organization focused on biopharmaceuticals.
This conference with the title "Fusion Proteins - delivering novel therapeutic options" is focused on the state of the art in developing fusion proteins as biopharmaceuticals, shedding light on the immense potential of design and functionality.
Fusion proteins belong to the most lucrative biotech drugs. The highly diverse pipeline is constantly growing with more than 80 molecules in clinical trials and five newly approved molecules in 2014 alone. This dynamic growth is primarily driven by three trends: Establishing platform technologies to extend plasma half-life, innovative approaches addressing multiple targets simultaneously and novel toxic constructs with superior selectivity. Therefore, it is worthwhile to dedicate a closer look to this exciting class of therapeutics.
A highlight of the event are the presentations by international speakers. Topics are among others toxic constructs, antibody derived molecules and bispecific scaffolds. At the first conference day, you will have the opportunity to participate at a tour of Rentschler’s facility. There will be also an industrial exhibition with companies showing their innovations and services. The deadline to register is 13 May 2016.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...